Akademik Veri Yönetim Sistemi
World Immune Regulation Meeting XVIII 2024, Chur, İsviçre, 13 - 16 Mart 2024, cilt.18, sa.57, ss.49-50
The coronavirus disease 2019 (COVID19) pandemic remains a significant public health challenge, with a possibility of progressing to severe disease with poor prognosis and mortality in risk groups. Identifying biomarkers for early prediction of the severity of COVID-19 progression would provide significant benefits, guiding patient care and allowing for early intervention prior to hospitalization. Our aim was to identify biomarkers that might predict severity, progression and mortality of the SARS-CoV-2 infection at the time of admission to the hospital. We evaluated the immune response, inflammation, cell regulation and organ damage proteins using a total of 372 biomarkers in sera from 328 COVID-19 patients and 49 controls. Patients were classified into mild (n=43), moderate (n=187) and severe groups (n=98) based on the clinical criteria. We identified five proteins associated with disease severity, including epithelial injury (KRT19, AREG and DSG4), inflammasome repressor (ZBTB16) and maintenance in pluripotency (LRRN1). The analysis of serum proteomics in 21 patients initially diagnosed with moderate disease, which later progressed to severe disease, identified six proteins linked to the progression of the illness (AUC: 0.84), including nucleoside hydrolysis (ENTPD6), epithelial-mesenchymal transition (HS3ST3B1), cytotoxicity regulation (LILRB4), cell-adhesion (PCDH17), resistance of cells to damage caused by hypoxia (STC1), and myocardial damage and heart failure (TNNI3). As an early predictor, these proteins were higher in both patients who progressed to severe disease and died. Moreover, the biomarkers that could be considered as predictors for the mortality of COVID-19 are cytokines (IL-7, IL-10), cytokine receptor (IL-10RB) and transmembrane signaling receptor (MILR1). This study expands our understanding of biological markers related to circulating inflammatory markers. This comprehensive approach not only elucidates the complex interplay between inflammation and immune response but also opens avenues for targeted therapeutic strategies that address both systemic and localized inflammation.